Collaborative for REsearch to Advance TMD Evidence (CREATE)

我们建议最终弥合我们对以下关系的理解上的差距： 颞下颌关节紊乱病（TMD）疼痛和潜在的机制，这将提供新的 TMD患者的诊断和治疗。我们设想，战区导弹防御系统合作， 改善以患者为中心的转化研究（TMD IMPACT）将满足以下需求： TMD预防，有效和个性化TMD治疗的发展，以及扩大 目前的工作力量，那些研究和管理TMD疼痛采取双向 翻译法我们对TMD IMPACT的愿景包括五个关键组成部分：1）临床 表型分析核心负责美国各地的临床中心，以协调患者 评估和分析，确保临床研究包括对 TMD患者，将用于识别TMD的表型数据的收集 预测潜在机制的亚型和生物标志物，以及患者结局， 对治疗干预的反应; 2）临床前核心，负责验证 临床前模型，建立机制和疼痛表型之间的因果关系， 治疗干预的初始疗效、特异性和安全性测试; 3）a数据和 生物样本管理核心，将协调不同数据类型的集成， 生物标本的存储，例如TMD IMPACT资源遵循公平原则，并提供 对未来TMD研究的长期影响; 4）教育和推广核心， 建立科学和临床劳动力能力，从而增加项目数量 进行临床前和临床TMD研究，扩大循证医学的可用性， 关心TMD患者，促进传播和实施 合作取得的进展;以及5）由患者/患者组成的利益相关者小组 倡导者，付款人和行业代表，他们将提供所有合作的反馈 努力在拟议的规划阶段，我们的合作研究推进TMD 证据（创建）团队将与其他选定的团队合作，奠定所需的基础 建立TMD-Collaborative并实现TMD-IMPACT的共同愿景。我们的一般 战略将是与为TMD-IMPACT计划选择的受资助的地点和中心进行接触 这是因为它们将拥有与联合国四个核心组成部分有关的专门知识和基础设施， 合作。

We propose to finally bridge the gap in our understanding of the relationship between temporomandibular disorder (TMD) pain and underlying mechanisms, which will provide new diagnostics and therapeutics for TMD patients. We envision that the TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT) will address the need for: TMD prevention, the development of effective and personalized TMD therapies, and expanding the current work force of those researching and managing TMD pain by taking a bidirectional translational approach. Our vision for TMD IMPACT involves five key components: 1) a Clinical Phenotyping Core responsible for Clinical Centers across the US, to coordinate patient assessment and analyses, ensure clinical studies include whole-person evaluations of individuals with a TMD, the collection of phenotypic data that will be used to identify TMD subtypes and biomarkers predictive of underlying mechanisms, and patient outcomes and response to therapeutic interventions; 2) a Preclinical Core responsible for the validation of preclinical models, establishing causal links between mechanisms and pain phenotypes, and for the initial efficacy, specificity, and safety testing of therapeutic interventions; 3) a Data and Biospecimen Management Core that will coordinate the integration of different data types and storage of biospecimens, such that TMD IMPACT resources follow FAIR principles and provide long-lasting impacts on TMD research into the future; 4) an Education and Outreach Core to build scientific and clinical workforce capacity, thereby increasing the number of programs pursuing preclinical and clinical TMD research, expanding the availability of evidence-based care for people living with a TMD, and promoting dissemination and implementation of advances made by the Collaborative; and 5) a Stakeholder Group consisting of patients/patient advocates, payers, and industry representatives who will provide feedback on all Collaborative efforts. During the proposed planning phase, our Collaborative for REsearch to Advance TMD Evidence (CREATE) team will work with the other selected teams to lay the groundwork needed to establish the TMD-Collaborative and achieve a shared vision for TMD-IMPACT. Our general strategy will be to engage with funded sites and centers chosen for the TMD-IMPACT planning phase, as they will have expertise and infrastructure relevant to the four core components of the Collaborative.